All In Biotech

Drug Trial Radar · NCT00029835

Obese Patients With Untreated Dyslipidemias

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias

Last checked: Nov 20, 2026Latest source record: Apr 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,033 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,033

Actual

Start

Sep 2001

Primary completion

Nov 2003

Study completion Nov 2003

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 24, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Conditions

  • Obesity
  • Dyslipidemia

Interventions

  • Rimonabant (SR141716)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weight at 1 year.

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinic of Physicians and Surgeons, LTD

    Mesa, Arizona

  • Arizona Clinical Research Center, Inc.

    Tucson, Arizona

  • Irvine Center for Clinical Research (ICCR)

    Irvine, California

  • Los Angeles Clinical Trials

    Los Angeles, California

  • Apexute

    Santa Ana, California

  • Clinical Research of South Florida

    Coral Gables, Florida

  • Radiant Research

    Stuart, Florida

  • nTouch Research

    Peoria, Illinois

  • nTouch Research

    South Bend, Indiana

  • Bluegrass Clinical Research, Inc.

    Louisville, Kentucky

  • Johns Hopkins Women's Research Core

    Lutherville, Maryland

  • Baystate Medical Center

    Springfield, Massachusetts

  • Twin Cities Clinical Research

    Arden Hills, Minnesota

  • Radiant Research

    Edina, Minnesota

  • Women's Clinic of Lincoln, PC

    Lincoln, Nebraska

  • New Mexico Clinical Research & Osteoporosis Center, Inc.

    Albuquerque, New Mexico

  • Clinical Research Services

    Bismarck, North Dakota

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Clinical Research Division

    Newtown, Pennsylvania

  • Clinical Research Center of Reading, LLC

    West Reading, Pennsylvania

  • Medical University of South Carolina, Division of Clinical Pharmacology

    Charleston, South Carolina

  • Nashville Medical Research Institute

    Nashville, Tennessee

  • Radiant Research

    Salt Lake City, Utah

  • Clinical Research Center of Northern Virginia

    Falls Church, Virginia

  • Hunter Holmes McGuire Medical Center Research Service (151)

    Richmond, Virginia

  • Vancouver Medical Weight Loss Clinic

    Vancouver, Washington

  • Addiction & Psychiatric Medicine Research

    Morgantown, West Virginia

  • Sanofi-aventis Administrative Office

    Macquarie Park, Australia

  • Sanofi-aventis Administrative Office

    Laval, Canada

  • Sanofi-aventis Administrative Office

    Helsinki, Finland

  • Sanofi-aventis Administrative Office

    Milan, Italy

  • Sanofi-aventis Administrative Office

    Barcelona, Spain

  • Sanofi-aventis Administrative Office

    Bromma, Sweden

  • Sanofi-aventis Administrative Office

    Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.